Year-End Report 2009

Highlights during the fourth quarter

• Biovitrum and Swedish Orphan announced the merger between the two companies, creating a leading specialty pharma company. The transaction was finalized on January 14, 2010, and Investor holds 41 percent in the combined listed company.
• Strong earnings momentum continued during the fourth quarter for Mölnlycke Health Care, Gambro, CaridianBCT and 3 Scandinavia.
• The Board of Directors proposes a dividend to shareholders of SEK 4.00 per share (4.00).

Financial information

• Net asset value amounted to SEK 142,673 m. (SEK 187 per share) on December 31, 2009, compared to SEK 115,233 m. (SEK 150 per share) at year-end 2008, corresponding to a change, with dividend added back, of 26 percent for 2009 (-23).
• Consolidated net profit for the year, including unrealized change in value, was SEK 31,368 m. (SEK 41.12 per share), compared to SEK -36,726 m. (SEK -47.98 per share) for 2008.
• Core Investments contributed SEK 31,851 m. to growth in net asset value in 2009 ( 31,546). All Core Investments had a positive impact, of which SEB had the largest, SEK 8,724 m.
• Operating Investments contributed SEK -1,380 m. to net asset value during 2009 (-144).
• Private Equity Investments contributed SEK 664 m. to growth in net asset value during 2009 (-3,463).
• The total return on the Investor share was 18 percent in 2009 ( 18). The total annual return averaged 13 percent over the past 5-year period.